Published in Cancer Weekly, September 14th, 2010
"About 18% to 37% of LLETZ specimens with dysplasia at the margins have recurrent/residual disease. Earlier small...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.